---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-25-000081"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:20:37.308081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission

## Summary
- Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).
- Cash, equivalents and marketable securities $367.4M at Sept 30, down from $588.0M at Dec 31, 2024.
- FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL; Phase 1 CATULUS data show 95% ORR.
- Phase 1 CARLYSLE data in lupus nephritis: 83% DORIS remission, no ICANS/high-grade CRS; Phase 2 LUMINA start expected by year-end.
- Leadership bolstered: Cintia Piccina US CCO, Miranda Neville CTO, Patrick McIlvenny CAO.

## SEC filing metadata
- accession: 0001730463-25-000081
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/0001730463-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/autl-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-25-000081
- JSON: https://secwatch.observer/filing/0001730463-25-000081.json
- Plain text: https://secwatch.observer/filing/0001730463-25-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.